Perfil de la empresa · Healthcare

Pfizer Inc

PFE · EE. UU.
Bolsa
EE. UU.
País / Región
USA
Fecha de salida a bolsa
22 de junio de 1942
Empleados
75.000
Precio actual
$25.21
En vivo · 18 de junio de 2026
Puntuación de crecimiento Baillie
40/100
Floja
Valor intrínseco · Rango en tres niveles Precio actual $25.21 En vivo · Dentro del rango de valor intrínseco razonable

Rango de valoración compuesto · conservador $16–$19 / razonable $24–$28 / optimista $32–$36. A $25.21, Dentro del rango de valor intrínseco razonable.

Al publicar $25.85 (25 de mayo de 2026)

Aún no hay análisis sobre este valor en tu idioma.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Capitalización147,73 mil MUS$
Ingresos (TTM)63,32 mil MUS$
EBITDA25,46 mil MUS$
Margen neto11,83 %
ROE8,31 %
PER (TTM)19,79
PER previsto8,79
PEG3,77
BPA1,31 US$
Rentabilidad por dividendo6,61 %
Rango de 52 semanas21,97 US$ – 28,28 US$
Precio objetivo de analistas29,19 US$
Recomendación de analistas3.6 / 5

Datos de EODHD, mostrados en la moneda de reporte; solo a título informativo, no constituye asesoramiento de inversión.

Historia

PróximamenteEsta sección se está completando; vuelve pronto.

Posición en el sector

PróximamenteEsta sección se está completando; vuelve pronto.